TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma
News Jan 11, 2010
TetraLogic Pharmaceuticals announced that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711.
The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
“The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
“This is an important milestone for our Company and for cancer patients,” said John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE